Exact Sciences
S01E103 : PRECISION ONCO 3/3 : EXACT SCIENCES
04 October 2026. The ledger bleeds open on Exact Sciences. We dissect the $21 billion Abbott buyout, the liquid biopsy mirage, and the grim reality of Medicare gatekeepers.
Exact Sciences
Exact Sciences
NOTES: Exact Sciences: The $21B Blood Mirage: Exact Sciences' Oncology Fleecing
Exposing the Adjusted EBITDA double-speak behind Exact Sciences' precision oncology pipeline and the structural trap of the early cancer detection market.
Exact Sciences
AUDIT: Exact Sciences: Blood and Bureaucracy: The Oncology Mirage
An objective analysis of Exact Sciences' $21 billion acquisition by Abbott Laboratories, examining the gap between precision oncology revenue and liquid biopsy reimbursement hurdles.